PTHS

SEC source: 0001753926-25-001109 · ownership.xml · derivative · entry 2

Baxter Richard B · CIK 0002075922 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,230

Underlying: Common Stock · 58,230 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

SEC source: 0001753926-25-001109 · ownership.xml · derivative · entry 1

Baxter Richard B · CIK 0002075922 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,108

Underlying: Common Stock · 19,108 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis thereafter over a period of three (3) years.

SEC source: 0001753926-25-001158 · ownership.xml · derivative · entry 2

Rangarao Sai · CIK 0002077227 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,000

Underlying: Common Stock · 93,000 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 93,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 93,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

SEC source: 0001753926-25-001158 · ownership.xml · derivative · entry 1

Rangarao Sai · CIK 0002077227 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,518

Underlying: Common Stock · 30,518 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 30,518 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 30,518 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

SEC source: 0001753926-25-001175 · ownership.xml · derivative · entry 2

Plesha Scott M. · CIK 0001726687 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 255,000

Underlying: Common Stock · 255,000 shares

Expires 2035-07-02

F2 · price: On July 2, 2025, the Reporting Person was granted stock options to purchase 255,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F2 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted stock options to purchase 255,000 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

SEC source: 0001753926-25-001175 · ownership.xml · derivative · entry 1

Plesha Scott M. · CIK 0001726687 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,678

Underlying: Common Stock · 83,678 shares

Expires 2035-07-02

F1 · price: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 83,678 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.exercise_date: On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 83,678 shares of common stock at an exercise price of $13.50 per share, with the initial one third (1/3) of such shares vesting on July 2, 2026, and in equal installments on a quarterly basis thereafter over a period of two (2) years.

SEC source: 0001753926-25-001884 · ownership.xml · derivative · entry 4

Pauls Matthew · CIK 0001573429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,985

Underlying: Common Stock · 8,493 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of issuer's Common Stock.

F1 · shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.exercise_date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.expiration_date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · derivative.underlying_shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years.

SEC source: 0001753926-25-001884 · ownership.xml · nonDerivative · entry 1

Pauls Matthew · CIK 0001573429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,493

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years.

F1 · shares: As previously reported on a Form 4 filed July 7, 2025, on July 2, 2025, the Reporting Person was granted 25,478 restricted stock units ("RSUs"), with the initial one third (1/3) of such shares vesting on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two (2) years.

SEC source: 0001919246-26-000041 · wk-form4a_1775079742.xml · nonDerivative · entry 1

Rangarao Sai · CIK 0002077227 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,518

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000039 · wk-form4a_1775079571.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,472

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000043 · wk-form4a_1775079819.xml · nonDerivative · entry 1

Greenleaf Peter · CIK 0001363683 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,478

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000046 · wk-form4a_1775079918.xml · nonDerivative · entry 3

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,886

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000042 · wk-form4a_1775079764.xml · nonDerivative · entry 1

Pauls Matthew · CIK 0001573429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,478

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of shares vested on July 2, 2025, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 3

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,585

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000044 · wk-form4a_1775079846.xml · nonDerivative · entry 1

Plesha Scott M. · CIK 0001726687 · Director · CEO and President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,678

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as an officer of the Issuer pursuant to the 2023 Plan. The RSUs vest as follows: the initial one-third of such shares vests on July 2, 2026, and the remainder vesting in equal installments on a quarterly basis thereafter over a period of two years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000045 · wk-form4a_1775079878.xml · nonDerivative · entry 3

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,012

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0001919246-26-000040 · wk-form4a_1775079720.xml · nonDerivative · entry 1

Baxter Richard B · CIK 0002075922 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,108

F1 · security: Represents shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4 filed by the reporting person (the "Original Form 4"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4 in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

SEC source: 0000950170-25-093589 · ownership.xml · derivative · entry 3

LIGAND PHARMACEUTICALS INC · CIK 0000886163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,278.681

Underlying: Common Stock · 3,127,868 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · shares: Received in exchange for shares of LNHC, Inc. common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, Inc., a wholly-owned subsidiary of the reporting person, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, the reporting person.

F2 · price: Received in exchange for shares of LNHC, Inc. common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, Inc., a wholly-owned subsidiary of the reporting person, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, the reporting person.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

SEC source: 0000950170-25-093589 · ownership.xml · derivative · entry 2

LIGAND PHARMACEUTICALS INC · CIK 0000886163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 1,500,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the reporting person may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the reporting person (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

SEC source: 0000950170-25-093589 · ownership.xml · nonDerivative · entry 1

LIGAND PHARMACEUTICALS INC · CIK 0000886163 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001753926-25-001077 · ownership.xml · derivative · entry 4

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001077 · ownership.xml · derivative · entry 3

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F4 · kind: Acquired in connection with cancellation of promissory note.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001077 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Camden Capital LLC

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Francis Knuettel II is the manager of Camden Capital LLC ("Camden") and the co-trustee of the Lara Knuettel Revocable Trust (the "Trust"). By virtue of these relationships, Mr. Knuettel may be deemed to beneficially own the shares of Common Stock held of record by each of Camden and the Trust. Mr. Knuettel disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001075 · ownership.xml · derivative · entry 4

Davis Todd C · CIK 0001392029 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,127,868

Underlying: Common Stock · 3,127,868 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F4 · shares: Received in exchange for shares of LNHC, Inc. ("LNHC") common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand.

F4 · price: Received in exchange for shares of LNHC, Inc. ("LNHC") common stock in connection with the merger of CHRO Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of the Issuer, with and into LNHC, a wholly-owned subsidiary of Ligand, with LNHC continuing as a wholly-owned subsidiary of the Issuer and the surviving corporation of the merger, pursuant to the Merger Agreement, dated as of April 16, 2025, by and among the Issuer, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001075 · ownership.xml · derivative · entry 3

Davis Todd C · CIK 0001392029 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,000

Underlying: Common Stock · 1,500,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 49.9% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001075 · ownership.xml · nonDerivative · entry 1

Davis Todd C · CIK 0001392029 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Ligand Pharmaceuticals Incorporated

Disclosed balance after: 1,500,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 7

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Key Recovery Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 6

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 5

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Key Recovery Group LLC

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001079 · ownership.xml · derivative · entry 4

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 40,000

Underlying: Common Stock · 92,072 shares

Expires not disclosed

F1 · derivative.exercise_price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · derivative.exercise_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F1 · derivative.underlying_shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F3 · balance_after: The Series A convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date. The Series A convertible preferred stock is subject to a contractual limitation such that the holder may not convert Series A convertible preferred stock to the extent that after giving effect to such conversion, the holder (together with its attribution parties as defined in the certificate of designations) would beneficially own in excess of 4.99% of the shares of common stock outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001079 · ownership.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Key Recovery Group LLC

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-001079 · ownership.xml · nonDerivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Balmoral Financial Group LLC

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · price: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F1 · balance_after: The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

F2 · ownership.nature: Ezra Friedberg is the manager of Balmoral Financial Group LLC ("Balmoral") and the manager of Key Recovery Group LLC ("Key"). By virtue of this relationship, Mr. Friedberg may be deemed to beneficially own the shares of Common Stock held of record by each of Balmoral and Key. Mr. Friedberg disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001753926-25-000643 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 430,736

Underlying: Common Stock · 53,988 shares

Expires 2035-04-11

F1 · security: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · date: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · shares: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · price: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · derivative.exercise_date: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · derivative.underlying_shares: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · balance_after: On April 11, 2025, the Reporting Person was granted stock options to purchase 53,988 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

SEC source: 0001753926-25-000644 · ownership.xml · derivative · entry 1

Simmons Chia-Lin · CIK 0001868194 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 25,000 shares

Expires 2035-04-11

F1 · security: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · date: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · shares: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · price: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · derivative.exercise_date: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · derivative.underlying_shares: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

F1 · balance_after: On April 11, 2025, the Reporting Person was granted stock options to purchase 25,000 shares of common stock at an exercise price of $1.35 per share, which shall vest in full in the event of a change of control transaction.

SEC source: 0001753926-24-001951 · ownership.xml · derivative · entry 1

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 263,306

Underlying: Common Stock · 49,605 shares

Expires 2024-11-13

F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 49,605 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

SEC source: 0001753926-24-001947 · ownership.xml · derivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 634,752

Underlying: Common Stock · 24,533 shares

Expires 2024-11-13

F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

SEC source: 0001753926-24-001949 · ownership.xml · derivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,098

Underlying: Common Stock · 24,533 shares

Expires 2024-11-13

F1 · price: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

F1 · derivative.exercise_date: On November 13, 2024, the Reporting Person was granted restricted stock units to purchase 24,533 shares of common stock at an exercise price of $0.64 per share, which shall vest on a quarterly basis over a period of six (6) quarters.

SEC source: 0001919246-26-000046 · wk-form4a_1775079918.xml · nonDerivative · entry 2

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,778

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001919246-26-000047 · wk-form4a_1775079936.xml · nonDerivative · entry 2

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,477

F1 · security: From June 18, 2024 to July 7, 2025, the reporting person filed multiple Form 4s relating to shares of common stock, par value $0.0001 per share ("Common Stock") of Pelthos Therapeutics Inc. (the "Issuer"), issuable upon settlement of restricted stock units of the Issuer ("RSUs") granted to the reporting person pursuant to the Issuer's 2023 Equity Incentive Plan, as amended from time to time (the "2023 Plan"), each of which represents the right to receive one (1) share of Common Stock, subject to the vesting terms of such RSUs, and may be settled solely in shares of Common Stock. The original grant of RSUs was reported in Table II of the Form 4s filed by the reporting person (the "Original Form 4s"). This Form 4 amendment (this "Amendment") is being filed to amend the Original Form 4s in order to report the grant of such RSUs in Table I.

F2 · shares: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F2 · price: The RSUs were received as compensation for the reporting person's service as a member of the Issuer's board of directors pursuant to the 2023 Plan. The RSUs vest in equal installments on a quarterly basis after the date of such grant for a period of three years, so long as the reporting person remains in the service of the Issuer on each such anniversary.

F3 · balance_after: Amounts have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

SEC source: 0001753926-24-001576 · ownership.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 547,710

F2 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.94 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

SEC source: 0001753926-24-001576 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 544,210

F1 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This price represents the weighted average price of the shares purchased ranging from $0.93 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

SEC source: 0001753926-24-001578 · ownership.xml · nonDerivative · entry 1

Malamut Richard · CIK 0001772168 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Jointly held with spouse

Disclosed balance after: 91,565

F1 · price: This price represents the weighted average price of the shares purchased ranging from $0.9206 to $0.9554 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

SEC source: 0001753926-24-001570 · ownership.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 542,510

F2 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.89 to $0.98 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

SEC source: 0001753926-24-001570 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO, Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · By Lara Knuettel Revocable Trust

Disclosed balance after: 537,010

F1 · price: This transaction is being reported to reflect the purchase of these shares by the Lara Knuettel Revocable Trust, of which the Reporting Person is co-trustee and has individual dispositive power. This sale price represents the weighted average sale price of the shares purchased ranging from $0.80 to $0.92 per share, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.

SEC source: 0001753926-24-001211 · ownership.xml · nonDerivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 515,510

SEC source: 0001753926-24-001211 · ownership.xml · nonDerivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 530,510

SEC source: 0001753926-24-001129 · ownership.xml · derivative · entry 2

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,778

Underlying: Common Stock · 324,000 shares

Expires 2034-06-14

F3 · price: On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F3 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted stock options to purchase 324,000 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

SEC source: 0001753926-24-001129 · ownership.xml · derivative · entry 1

Francis Knuettel II · CIK 0001433316 · CEO, Pres., CFO Treas & Secty

10b5-1 filing: No plan indicated

Ownership: Indirect · Camden Capital LLC

Disclosed balance after: 52,778

Underlying: Common Stock · 27,778 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, Camden Capital LLC was granted stock options to purchase 27,778 shares of common stock at an exercise price of $1.30 per share, which were fully vested.

F2 · ownership.nature: The securities are held by Camden Capital LLC. The Reporting Person, as the manager of Camden Capital LLC, is deemed to be a beneficial owner of these securities.

SEC source: 0001753926-24-001127 · ownership.xml · derivative · entry 1

Davis Todd C · CIK 0001392029 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,701

Underlying: Common Stock · 128,977 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 128,977 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 128,977 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

SEC source: 0001753926-24-001133 · ownership.xml · derivative · entry 1

Friedberg Ezra M · CIK 0001679440 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 610,219

Underlying: Common Stock · 64,498 shares

Expires 2034-06-14

F1 · price: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.

F1 · derivative.exercise_date: On June 14, 2024, the Reporting Person was granted restricted stock units to purchase 64,498 shares of common stock at an exercise price of $1.30 per share, which shall vest on a quarterly basis over a period of two (2) years.